Hanmi Pharm is developing the salt alteration product of Tamifly to avoid the patent

Hanmi Pharm has begun to develop the salt alteration product of the flu treatment, Tamiflu.

This is because it is trying to avoid the Roche’s salt patent for Tamiflu; the decisions between Hanmi Pharm and other domestic pharmaceutical companies that have applied generic approvals are expected to be judged in February of the next year.

According to the Ministry of Food and Drug Safety on the 1...